# Bicycle Continued Access Protocol (BiCAP) for Participants Receiving a Bicycle Investigational Product

> **NCT07681674** · PHASE2 · NOT_YET_RECRUITING · sponsor: **BicycleTx Limited** · enrollment: 16 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** Zelenectide pevedotin
- **DRUG:** BT7480
- **DRUG:** Nuzefatide pevedotin

## Key facts

- **NCT ID:** NCT07681674
- **Lead sponsor:** BicycleTx Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-01
- **Primary completion:** 2030-05-30
- **Final completion:** 2030-05-30
- **Target enrollment:** 16 (ESTIMATED)
- **Last updated:** 2026-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07681674

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07681674, "Bicycle Continued Access Protocol (BiCAP) for Participants Receiving a Bicycle Investigational Product". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07681674. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*